Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting1
Not yet recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

active_not_recruiting125%
not_yet_recruiting125%
recruiting125%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

NCT07557121
recruitingphase_3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759
active_not_recruitingphase_3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
completedphase_2

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

NCT05275205

Clinical Trials (4)

Showing 4 of 4 trials
NCT07557121Phase 2

Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration

Not Yet Recruiting
NCT07064759Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Recruiting
NCT06864988Phase 3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Active Not Recruiting
NCT05275205Phase 2

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4